Methyl Jasmonate

Methyl jasmonate is a plant-derived cyclopentanone signaling molecule from jasmine that activates jasmonate signaling pathways involved in stress response and apoptosis. Research focuses on its ability to selectively induce programmed cell death in cancer cells by targeting mitochondrial pathways without affecting normal cells.

Origin & History

Methyl jasmonate (MeJA) is a volatile organic compound derived from jasmonic acid, belonging to the jasmonate class of plant hormones with formula C13H20O3. First isolated from Jasminum grandiflorum petals where it constitutes 2-3% of jasmine oil, it is produced through biosynthesis starting with linolenic acid oxidation in chloroplasts, followed by peroxisomal β-oxidation and cytoplasmic methylation.

Historical & Cultural Context

No historical context or uses in traditional medicine systems are documented in the available research sources.

Health Benefits

• Potential cancer treatment applications (evidence quality: preliminary research only, no human trials available) • Plant-derived signaling molecule under investigation for therapeutic properties (evidence quality: no clinical evidence) • Natural compound from jasmine with bioactive potential (evidence quality: no human studies identified) • Subject of early research for medicinal applications (evidence quality: no RCTs or clinical data) • Volatile organic compound with theoretical health applications (evidence quality: no human trials documented)

How It Works

Methyl jasmonate induces apoptosis in cancer cells by directly targeting the mitochondrial permeability transition pore, causing cytochrome c release and activation of caspase-3 and caspase-9. It detaches the glycolytic enzyme hexokinase from the mitochondrial outer membrane, disrupting the Warburg effect that cancer cells depend on for energy. Additionally, it modulates reactive oxygen species (ROS) accumulation and suppresses Bcl-2 anti-apoptotic proteins, shifting the Bax/Bcl-2 ratio toward cell death.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses were identified for methyl jasmonate in the available research. The compound is noted as being under early research for potential cancer treatment in humans, but no specific study designs, sample sizes, outcomes, or PubMed PMIDs are available.

Clinical Summary

Research on methyl jasmonate remains almost entirely preclinical, confined to in vitro cell line studies and rodent models with no completed human clinical trials published as of 2024. In vitro studies using concentrations of 1–3 mM have demonstrated cytotoxic effects against breast, prostate, and leukemia cell lines, with selective toxicity favoring cancer cells over normal cells at specific dose ranges. Animal model studies in mice have shown tumor growth inhibition, but pharmacokinetics, bioavailability, and safe dosing ranges in humans remain undefined. The evidence base is too preliminary to support any therapeutic claims, and the compound is not approved as a medical treatment by the FDA or EMA.

Nutritional Profile

Methyl Jasmonate (MeJA) is a pure bioactive signaling compound (cyclopentanone derivative), not a nutritional ingredient, so conventional macronutrient/micronutrient profiling does not apply. Molecular formula: C13H20O3, molecular weight: 224.30 g/mol. It is a methyl ester of jasmonic acid, belonging to the jasmonate class of oxylipins. As a pure compound, it contains no protein, fiber, vitamins, or dietary minerals. Caloric contribution is negligible at physiological exposure concentrations. Primary bioactive identity: cyclopentane ring with a pentenyl side chain and methyl ester group, conferring its biological signaling activity. Naturally occurs in jasmine (Jasminum spp.) essential oils at concentrations of approximately 0.5–3% by composition, and in trace amounts across other plant species as a volatile phytohormone. Bioavailability data from human studies is absent; in vitro and animal studies suggest lipophilic character (estimated logP ~2.5) facilitates membrane permeability. At research concentrations (typically 10–1000 µM in cell studies), it modulates stress-response pathways including JA signaling cascades and apoptotic pathways. No established dietary reference intake or tolerable upper limit exists. Not a source of essential nutrients.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available from human studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical research

Safety & Interactions

Human safety data for supplemental methyl jasmonate is essentially absent, as no formal phase I or phase II clinical trials have established a safe dose range or adverse event profile in humans. Topical exposure in cosmetic contexts has rarely been associated with skin sensitization, but oral or systemic use lacks a documented safety record. Potential interactions with chemotherapy agents or anticoagulants are theoretically plausible given its pro-apoptotic and mitochondrial mechanisms, but no interaction studies exist. Pregnant and breastfeeding individuals should strictly avoid methyl jasmonate supplements due to complete absence of reproductive safety data.